Bal Pharma skyrockets 8.5% after ICRA upgrades rating on its credit facilities

The rating on long-term fund-based facilities of the company has been upgraded to ICRA BB+; Stable.

Sep 15, 2021 03:09 IST India Infoline News Service

Stock-market-bull
ICRA Limited has upgraded the credit rating of Bal Pharma Limited. The rating on long-term fund-based facilities of the company has been upgraded to ICRA BB+; Stable from ICRA BB Stable. The rating on short-term non-fund-based facilities of the company has been upgraded to ICRA A4+ from ICRA A4.

The credit rating agency also upgraded the long-term Term Loan of the company to ICRA BB+; Stable from ICRA BB; Stable.

The company stock was in demand on Wednesday and towards end of the trade, it was trading at Rs106.45 per piece up by Rs8.35 or 8.51% from its previous closing of Rs98.10 per piece on the BSE. The scrip opened at Rs102.80 and has touched a high and low of Rs107.90 and Rs102.40 respectively.

The credit rating agency has considered the following material event’s for up-gradation of the credit rating, the company said.

Established position as a leading manufacturer of API for anti diabetic drug i.e Gliclazide and diversified customer base in API and formulations segments.
Improvement in revenue and profitability for FY21 and Q1FY22.
Expected further equity infusion by the promoters during F.Y 2022.

Higher working capital intensity, intense competition in domestic and exports markets for API’s, moderate capitalization and coverage indicators, import dependance on China for raw materials for manufacture of Gliclazide are some of the credit challenges highlighted by the rating agency.

Related Story

Open Free Demat Account (Rs699)